东诚药业8月26日公告，公司董事会当天收到公司副总经理吴晓明的书面辞职报告，吴晓明由于工作调 整原因，申请辞去公司副总经理职务，辞职后仍担任公司控股子公司烟台蓝纳成生物技术股份有限公司 执行董事、总经理。吴晓明的辞职报告自送达公司董事会之日起生效。 ...

Group 1 - Dongcheng Pharmaceutical (002675.SZ) is rated as a "Buy" by Dongwu Securities due to strong growth in its core nuclear medicine products and improved product structure leading to increased net profit margins [1] - The company is in a harvest phase for its innovative nuclear medicine platform pipeline, with advanced progress in nuclear medicine research and development [1] Group 2 - The report highlights potential risks including slower-than-expected new drug development, nuclear medicine policy reforms, exchange rate fluctuations, and price volatility in heparin raw materials, as well as increased depreciation impacting performance [1]

顾家家居：上半年净利润10.21亿元 同比增长13.89% 8月22日晚，顾家家居（603816）发布2025年半年度报告，公司上半年实现营业收入98.01亿元，同比增 长10.02%；实现归属于上市公司股东的净利润10.21亿元，同比增长13.89%；基本每股收益为1.26元/ 股。 资料显示，顾家家居成立于2006年10月，主营业务是客厅、餐厅、卧室、整家定制等全场景家居产品的 研究、设计、开发、生产、销售与服务。 所属行业：轻工制造–家居用品–成品家居 凤凰股份：上半年净利润1103.54万元 成功扭亏 8月22日晚，凤凰股份（600716）发布2025年半年度报告，公司上半年实现营业收入2.91亿元，同比增 长200.78%；实现归属于上市公司股东的净利润1103.54万元，成功扭亏为盈；基本每股收益为0.0118元/ 股。 资料显示，凤凰股份成立于1996年6月，主营业务是房地产开发与销售。 所属行业：房地产–房地产开发–住宅开发 浙商证券：上半年净利润11.49亿元 同比增长46.49% 8月22日晚，浙商证券（601878）发布2025年半年度报告，公司上半年实现营业收入61.07亿元，同比下 ...

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary LNC PHARMA PTE.LTD. received FDA approval for the clinical trial of 225Ac-LNC1011 injection, which will soon commence Phase I clinical trials [1] Summary by Relevant Sections - **FDA Approval**: The FDA has completed the safety review of the 225Ac-LNC1011 injection application and has issued a Study May Proceed Letter (SMP), allowing the proposed prostate cancer clinical study to move forward [1] - **Next Steps**: Following the issuance of the SMP, the 225Ac-LNC1011 injection must undergo clinical trials and receive FDA review and approval before it can be marketed and sold in the United States [1]

（文章来源：每日经济新闻） 2025年1至6月份，东诚药业的营业收入构成为：生物制药行业占比100.0%。 东诚药业（SZ 002675，最新价：17.56元）8月22日午间发布公告称，公司下属公司LNC PHARMA PTE. LTD.（简称"蓝纳成药业"）收到美国食品药品监督管理局核准签发的关于Ac-LNC1011 注射液的药品临 床试验批准通知书 (Study May Proceed Letter)，将于近期开展I期临床试验。 ...

【东诚药业：下属公司获药物临床试验批准通知书】智通财经8月22日电，东诚药业午间公告，8月22 日，公司下属公司LNC PHARMA PTE. LTD.（简称"蓝纳成药业"）收到美国食品药品监督管理局（简 称"FDA"）核准签发的关于225Ac-LNC1011注射液的药品临床试验批准通知书，将于近期开展I期临床 试验。该药物拟用于治疗PSMA阳性表达的晚期前列腺癌患者。 转自：智通财经 ...

Core Viewpoint - Yantai Dongcheng Pharmaceutical Group Co., Ltd. announced that its subsidiary LNC PHARMA PTE. LTD. received FDA approval for the clinical trial of 225Ac-LNC1011 injection, which will soon commence Phase I clinical trials [1][2]. Drug Information - The drug 225Ac-LNC1011 is an injectable formulation intended for the treatment of advanced prostate cancer expressing Prostate Specific Membrane Antigen (PSMA) [2]. - The drug utilizes alpha particle radiation therapy, which has a short range (<100 μm) and high energy deposition (80-100 keV/μm), providing stronger cell-killing effects on tumors while minimizing damage to surrounding healthy tissues [2]. - Previous animal and human trials have shown excellent pharmacokinetic properties and significant efficacy, indicating its potential as a more effective PSMA-targeted therapy for metastatic castration-resistant prostate cancer (mCRPC) [2]. Financial Investment - The total research and development expenses incurred for the 225Ac-LNC1011 project to date amount to approximately 14.1648 million yuan [3].

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary LNC PHARMA PTE. LTD. received FDA approval for the clinical trial of 225Ac-LNC1011 injection, with Phase I trials to commence shortly [1] Group 1 - The FDA issued a Study May Proceed Letter (SMP) for the clinical trial of 225Ac-LNC1011 injection [1] - The clinical trial is set to begin in the near future [1]

人民财讯8月22日电，东诚药业（002675）8月22日午间公告，8月22日，公司下属公司LNC PHARMA PTE.LTD.(简称"蓝纳成药业")收到美国食品药品监督管理局(简称"FDA")核准签发的关于225Ac- LNC1011注射液的药品临床试验批准通知书，将于近期开展I期临床试验。该药物拟用于治疗PSMA阳 性表达的晚期前列腺癌患者。 ...

FDA已完成对225Ac-LNC1011注射液申请的安全性审核，并认为可以继续进行拟议的前列腺癌临床研 究。根据美国药品注册相关的法律法规要求，225Ac-LNC1011注射液在获得SMP后，尚需开展临床试验 并经FDA审评、审批通过后方可在美国上市销售。 智通财经APP讯，东诚药业(002675.SZ)发布公告，2025年8月22日，公司下属公司LNC PHARMA PTE. LTD. (简称"蓝纳成药业")收到美国食品药品监督管理局(简称"FDA")核准签发的关于225Ac-LNC1011注 射液的药品临床试验批准通知书(Study May Proceed Letter，简称"SMP")，将于近期开展I期临床试验。 ...